Ulrik Niels Lassen

Ulrik Niels Lassen

Clinical Professor

Member of:

  • Clinical Oncology


Publication year:
All
41 - 50 out of 159Page size: 10
Sort by: Title
  1. Published

    Concordance of mutation detection in circulating tumor DNA in early clinical trials using different blood collection protocols

    Ahlborn, L. B., Madsen, M., Jonson, L., Nielsen, Finn Cilius, Lassen, Ulrik Niels, Yde, C. W. & Mau-Sorensen, M., 2017, In: Clinical Laboratory. 63, 10, p. 1755-1759

    Research output: Contribution to journal › Journal article › Research › peer-review

  2. Published

    Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

    Jacobsen, K., Bertran-Alamillo, J., Molina, M. A., Teixidó, C., Karachaliou, N., Pedersen, M. H., Castellví, J., Garzón, M., Codony-Servat, C., Codony-Servat, J., Giménez-Capitán, A., Drozdowskyj, A., Viteri, S., Larsen, M. R., Lassen, Ulrik Niels, Felip, E., Bivona, T. G., Ditzel, H. J. & Rosell, R., 2017, In: Nature Communications. 8, 14 p., 410.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Copenhagen prospective personalized oncology (COPPO)—Clinical utility of using molecular profiling to select patients to phase I trials

    Tuxen, I. V., Rohrberg, K. S., Oestrup, O., Ahlborn, L. B., Schmidt, A. Y., Spanggaard, I., Hasselby, Jane Preuss, Santoni Rugiu, Eric, Yde, C. W., Mau-Sørensen, M., Nielsen, Finn Cilius & Lassen, Ulrik Niels, 2019, In: Clinical Cancer Research. 25, 4, p. 1239-1247 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Copenhagen prospective personalized oncology (CoPPO): Genomic profiling to select patients for phase 1 trials

    Tuxen, I. V., Yde, C. W., Mau-Sorensen, M., Santoni Rugiu, Eric, Lassen, Ulrik Niels & Nielsen, Finn Cilius, 2016, In: Annals of Oncology.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Copenhagen prospective personalized oncology (CoPPO): Sequencing and array-based pipeline for selection of patients to phase 1 studies

    Tuxen, I. E. V., Santoni Rugiu, Eric, Joenson, L., Vikesaa, J., Mau-Soerensen, M., Nielsen, Finn Cilius & Lassen, Ulrik Niels, 2014, In: Journal of Clinical Oncology.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Criteria for site selection in industry-sponsored clinical trials: a survey among decision-makers in biopharmaceutical companies and clinical research organizations

    Dombernowsky, T., Hædersdal, Merete, Lassen, Ulrik Niels & Thomsen, Simon Francis, 2019, In: Trials. 20, 12 p., 708.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Current therapy of small cell lung cancer

    Sorensen, M., Lassen, Ulrik Niels & Hansen, H. H., Mar 1998, In: Current Opinion in Oncology. 10, 2, p. 133-8 6 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

    Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Gazzah, A., Lassen, U., Stein, A., Wen, P. Y., Dietrich, S., de Jonge, M. J. A., Blay, J-Y., Italiano, A., Yonemori, K., Cho, D. C., de Vos, F. Y. F. L., Moreau, P., Fernandez, E. E., Schellens, J. H. M., Zielinski, C. C., Redhu, S., Boran, A. & 3 others, Passos, V. Q., Ilankumaran, P. & Bang, Y., 2023, In: Nature Medicine. 29, 5, p. 1103-1112 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

    Subbiah, V., Lassen, Ulrik Niels, Élez, E., Italiano, A., Curigliano, G., Javle, M., De Braud, F., Prager, G. W., Greil, R., Stein, A., Fasolo, A., Schellens, J. H. M., Wen, P. Y., Viele, K., Boran, A. D., Gasal, E., Burgess, P., Ilankumaran, P. & Wainberg, Z. A., 1 Sep 2020, In: The Lancet Oncology. 21, 9, p. 1234-1243 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer – Authors' reply

    Subbiah, V., Lassen, Ulrik Niels, Gasal, E., Burgess, P. & Wainberg, Z. A., 1 Nov 2020, In: The Lancet Oncology. 21, 11, p. e516 1 p.

    Research output: Contribution to journal › Comment/debate › Research

Previous 1 2 3 4 5 6 7 8 ...16 Next

ID: 4952653